Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

This is a non-randomized, phase-II study of platinum doublet chemotherapy plus ramucirumab in patients with advanced NSCLC who have progressed on first line anti-PD-1 Immunotherapy. Up to 25 evaluable participants will be enrolled over a period of 2 years. Seven patients will be recruited at the first stage .Eligible patients …

neutrophil count
cancer chemotherapy
pd-1 inhibitor
cancer treatment
lung carcinoma
  • 1 views
  • 25 Jan, 2021
  • 1 location
Sponge and Eosinophil Peroxidase (EPO) Staining

Are we able to use the EPO staining technique using the sponge ?

elimination diet
  • 0 views
  • 15 May, 2021
  • 1 location
EoE Food Desensitization

This is a single-center, prospective, pilot clinical trial in which children ages 3-17 years with eosinophilic esophagitis (EoE) who have a known food that triggers EoE flares receive oral desensitization with that specific food antigen, followed by reintroduction of that food into the diet. The purpose of this study is …

  • 5 views
  • 05 Jul, 2021
  • 1 location
Deflazacort vs. Prednisolone in Acute-stage ABPA

Oral glucocorticoids are currently the treatment of choice for allergic bronchopulmonary aspergillosis (ABPA). They not only suppress the immune hyperfunction but are also anti-inflammatory. Unfortunately, numerous toxicities and adverse effects have been attributed to glucocorticoids related to both the average dose and cumulative duration of use. Deflazacort is a oxazoline …

  • 2 views
  • 28 Feb, 2021
  • 1 location
Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy

The aim of the study is: to evaluate the serum levels of miR-223 and miRNA146a and to assess their correlation with disease severity in allergic rhinitis patients and their role as biomarkers for efficacy of sublingual immunotherapy. also to find if high sensitivity CRP can be an easy non-expensive test …

  • 0 views
  • 22 Sep, 2021
  • 1 location
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count. The treatment period will be of variable duration

severe chronic obstructive pulmonary disease
corticosteroids
eosinophil count
antibiotics
bronchodilator
  • 838 views
  • 10 Sep, 2021
  • 439 locations
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)

This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting 2-agonist (ICS-LABA) with or without …

benralizumab
corticosteroids
theophylline
fluticasone
leukotriene receptor antagonist
  • 696 views
  • 04 Sep, 2021
  • 65 locations
Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)

patterns cannot be distinguished reliably by clinical categories (i.e. asthma or COPD) or a standard clinical assessment but are identified by the peripheral blood eosinophil count. These findings raise

  • 0 views
  • 20 May, 2021
  • 1 location
Benralizumab Initiated During Severe Asthma Attack

times higher than OECD countries. Spot Blood eosinophil count (BEC) during an acute exacerbation of asthma was a predictor of more severe respiratory failure and was associated with future acute health

  • 0 views
  • 01 Aug, 2021
  • 1 location
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial

This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.

  • 0 views
  • 26 Jan, 2021
  • 1 location